Pivotal phase II study of resiniferatoxin for the treatment of cancer pain

Trial Profile

Pivotal phase II study of resiniferatoxin for the treatment of cancer pain

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Resiniferatoxin (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2017, as per Scintilla Pharmaceuticals media release.
    • 08 Aug 2016 According to a Scintilla Pharmaceuticals media release, this study is expected to initiate in early 2017.
    • 20 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top